Clinical trials of the past decade in the management of chronic kidney disease

Reviews on Recent Clinical Trials

Volumn 4, Issue 3, 2009, Pages 159-162

  Woo, Keng Thye ^a   Kok Seng, ^a   Chan, Choong Meng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Glomerular filtration rate; High dose angiotensin receptor blockers; Proteinuria

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; COLESTYRAMINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; LOSARTAN; METHYLDOPA; RAMIPRIL; SIMVASTATIN; TELMISARTAN;

BLOOD PRESSURE REGULATION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOSARTAN; PROTEINURIA; RENAL REPLACEMENT THERAPY;

EID: 73349125495     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488709789957646     Document Type: Review

References (22)

1. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76: 23-31.
2. Fifth Report of the Singapore Renal Registry (2004) Singapore: Health Promotion Board 2008; p. 24.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
4. Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and β-blocking agents. Nephron 1991; 59: 57-60.
5. Morelli E, Loon N, Meyer TW, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy . Diabetes 1990; 39: 76-82.
6. Woo KT, Lau YK, Wong KS, Chiang GSC. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000; 58: 2485-91.
7. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Anderswn S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
8. Bakris GL. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-61.
9. Pohl MA. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-37.
10. Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
11. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
12. Sarnak MJ, Greene T, Wang X. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-51.
13. Forman JP, Brenner BM. 'Hypertension" and 'microalbuminuria': the bell tolls for thee. Kidney Int 2006; 69: 22-8.
14. Lea J, Greene T, Hebert L. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-53.
15. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988; 33: 917-24.
16. Tonolo G, Velussi M, Brocco E. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006, 70:177-86.
17. Parving HH. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46.
18. Woo KT, Chan CM, Wong KS, et al. High dose Losartan and ACE gene polymorphism in IgA nephritis. Genomic Med 2009; 2(3): 77-81.
19. Vleming LJ, Van Kooten C, Van Dijk M, et al. The D- allele of the ACE gene polymorphism predicts a stronger antiproteimuric response to ACE inhibitors. Nephrology 1998; 4: 143-9.
20. Woo KT, Chan CM, Wong KS, et al. Beneficial effects of high dose losartan in IgA nephritis. Clin Nephrol 2009; 71 (6): 617-24.
21. ONTARGET Investigators. Telmisartan , ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
22. Hamming I, Van Goor H, Navis GJ. ACE inhibitor use and the increased long term risk of renal failure in diabetes. Kidney Int 2006; 70: 1377-8.